pentoxifylline has been researched along with Atherogenesis in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Inflammation is involved in development, progression, and complications of atherosclerotic disease." | 6.79 | Pentoxifylline decreases serum level of adhesion molecules in atherosclerosis patients. ( Allah Abadi, G; Falsoleiman, H; Mohammadpour, AH; Ramezani, M; Rasooli, R; Shamsara, J, 2014) |
| "Early atherosclerosis was observed in rats with NASH induced by a 16-week high-fat diet." | 5.36 | Pentoxifylline alleviates high-fat diet-induced non-alcoholic steatohepatitis and early atherosclerosis in rats by inhibiting AGE and RAGE expression. ( Jiang, Y; Wu, J; Zhang, H; Zhao, MY; Zheng, H, 2010) |
| "Pentoxifylline (PTX) is an inhibitor of cytokines and PAF and would reduce the generation of ROS by granulocytes and endothelial cells." | 5.34 | Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism. ( Lee, P; Prasad, K, 2007) |
| "Inflammation is involved in development, progression, and complications of atherosclerotic disease." | 2.79 | Pentoxifylline decreases serum level of adhesion molecules in atherosclerosis patients. ( Allah Abadi, G; Falsoleiman, H; Mohammadpour, AH; Ramezani, M; Rasooli, R; Shamsara, J, 2014) |
| "Early atherosclerosis was observed in rats with NASH induced by a 16-week high-fat diet." | 1.36 | Pentoxifylline alleviates high-fat diet-induced non-alcoholic steatohepatitis and early atherosclerosis in rats by inhibiting AGE and RAGE expression. ( Jiang, Y; Wu, J; Zhang, H; Zhao, MY; Zheng, H, 2010) |
| "Pentoxifylline (PTX) is an inhibitor of cytokines and PAF and would reduce the generation of ROS by granulocytes and endothelial cells." | 1.34 | Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism. ( Lee, P; Prasad, K, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elseweidy, MM | 1 |
| Elswefy, SE | 1 |
| Younis, NN | 1 |
| Tarek, S | 1 |
| Mohammadpour, AH | 1 |
| Falsoleiman, H | 1 |
| Shamsara, J | 1 |
| Allah Abadi, G | 1 |
| Rasooli, R | 1 |
| Ramezani, M | 1 |
| Wu, J | 1 |
| Zhao, MY | 1 |
| Zheng, H | 1 |
| Zhang, H | 1 |
| Jiang, Y | 1 |
| Prasad, K | 1 |
| Lee, P | 1 |
| Lipsitz, EC | 1 |
| Kim, S | 1 |
1 trial available for pentoxifylline and Atherogenesis
| Article | Year |
|---|---|
Pentoxifylline decreases serum level of adhesion molecules in atherosclerosis patients.
Topics: Atherosclerosis; Cell Adhesion Molecules; Chemokine CCL2; Double-Blind Method; Female; Humans; Infla | 2014 |
4 other studies available for pentoxifylline and Atherogenesis
| Article | Year |
|---|---|
The modulation of PCSK-9 and GAGs by 10-dehydrogingerdione and pentoxifylline in hyperlipidemic rabbits.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Cholesterol; Glycosaminoglycans; Guaiacol; Hyper | 2020 |
Pentoxifylline alleviates high-fat diet-induced non-alcoholic steatohepatitis and early atherosclerosis in rats by inhibiting AGE and RAGE expression.
Topics: Animals; Atherosclerosis; Dietary Fats; Fatty Liver; Gene Expression Regulation; Glycation End Produ | 2010 |
Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism.
Topics: Animals; Antioxidants; Aorta; Atherosclerosis; Body Weight; Butylene Glycols; Cholesterol, Dietary; | 2007 |
Antithrombotic therapy in peripheral arterial disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Cilostazol; Clopidogrel; Comorbidity; Diabetic Angiopathie | 2008 |